Scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed an efficient process to rapidly discover new “enediyne natural products” from soil microbes that could be further developed into extremely potent anticancer drugs.
The study highlights microbial natural products as abundant sources of new drug leads. The researchers’ discovery process involves prioritizing the microbes from the TSRI strain collection and focusing on the ones that are genetically predisposed to produce specific families of natural products. The scientists say this process saves time and resources in comparison to the traditional approaches used to identify these rare molecules.
The study, led by TSRI Professor Ben Shen, was published today in the journal mBio.
Shen and his colleagues uncovered a new family of enediyne natural products, called tiancimycins, (TNMs) which kill selected cancer cells more rapidly and completely in comparison to toxic molecules used in FDA-approved antibody-drug conjugates (ADCs)— monoclonal antibodies attached to cytotoxic drugs that target only cancer cells.
The scientists also discovered several new producers of C-1027, an antitumor antibiotic currently in clinical development, which can produce C-1027 at much higher levels.
It has been more than a decade since Shen first reported on the C-1027 enediyne biosynthetic machinery, and he speculated then that the knowledge obtained from studying biosynthesis of C-1027, and other enediynes, could be used for the discovery of novel enediyne natural products.
“The enediynes represent one of the most fascinating families of natural products for their extraordinary biological activities,” Shen said. “By surveying 3,400 strains from the TSRI collection, we were able to identify 81 strains that harbor genes encoding enediynes. With what we know, we can predict novel structural insights that can be exploited to radically accelerate enediyne-based drug discovery and development.”
“The work described by the Shen group is an excellent example of what can be achieved by coupling state of the art genomic analyses of potential biosynthetic clusters and modern physicochemical techniques,” said David J. Newman, retired chief of the National Cancer Institute’s Natural Products Branch. “As a result of their work, the potential number of enediynes has significantly increased.”
Shen’s method of strain prioritization and genome mining means a far more efficient use of resources involved in the discovery process, targeting only those strains that look to produce the most important natural compounds.
“This study shows that the potential to rapidly discover new enediyne natural products from a large strain collection is within our reach,” said TSRI Research Associate Xiaohui Yan, one of four first authors of the study. “We also show the feasibility of manipulating tiancimycin biosynthesis in vivo, which means that sufficient quantities of these precious natural products can be reliably produced by microbial fermentation for drug development and eventual commercialization.”
Receive an email update when we add a new ANTI-CANCER DRUG article.
The Latest on: Anticancer drug
via Google News
The Latest on: Anticancer drug
- Sunshine Biopharma Signs an Agreement with Crocus Laboratories for Manufacturing of Adva-27a Anticancer Drug on December 12, 2018 at 6:53 am
MONTREAL, QC / ACCESSWIRE / December 12, 2018 / Sunshine Biopharma, Inc. (OTC PINK: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatmen... […]
- Gibson’s Novel Anti-cancer Drug, LMP-400, Receives FDA Rare Pediatric Disease Designation for the Treatment of Ewing Sarcoma on December 12, 2018 at 3:30 am
Gibson Oncology, LLC (“Gibson”), a privately held clinical stage company developing a novel class of oncology drugs for treating adult and pediatric cancers resistant to traditional cancer drugs, anno... […]
- Chemotherapy Induced Anemia Drug industry analysis by revenue and market share available in new report on December 10, 2018 at 12:14 pm
Global Chemotherapy Induced Anemia Drug Market Report analyze the key factor like market status, market share, growth rate, future trends, market drivers, opportunities, challenges and more. Global Ch... […]
- Scientists to produce anti-cancer drugs in yeast on December 7, 2018 at 12:38 pm
Nature is so complex that natural molecules used for i.e. cancer treatment still can't be produced by chemical synthesis. Today, major chemical and pharmaceutical companies harvest large amounts of ra... […]
- FDA Approves Genentech’s Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer on December 6, 2018 at 4:05 pm
RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Tecentriq ® (atezolizumab), in combination with Avastin ® (bevacizumab), paclitaxel and carboplatin (chemotherapy), fo... […]
- DnaK: A Bacterial Protein Involved In Anticancer Drug-resistance on December 6, 2018 at 10:10 am
DnaK, a protein of the bacterium mycoplasma, interferes with the mycoplasma-infected cell’s ability to respond to and repair DNA damage, a known origin of cancer, the Institute of Human Virology (IHV) ... […]
- Stimulated Development of Orphan Drug Designations for Rare Diseases and Anti-Cancer Drug Candidates Intensifies on December 6, 2018 at 4:30 am
PALM BEACH, Florida, December 6, 2018 /PRNewswire via COMTEX/ -- PALM BEACH, Florida, December 6, 2018 /PRNewswire/ -- The FDA is committed to doing what is can to stimulate the development of more pr... […]
- Global Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Insights, Epidemiology and Market Forecast, 2027 - ResearchAndMarkets.com on December 5, 2018 at 12:26 pm
DUBLIN--(BUSINESS WIRE)--Dec 5, 2018--The "Chemotherapy-Induced Peripheral Neuropathy (CIPN) - Market Insights, Epidemiology and Market Forecast" drug pipelines has been added to ResearchAndMarkets.co... […]
- Open source tool picks best chemo drug 80% of the time on December 4, 2018 at 6:09 am
A new machine learning tool could help find the chemotherapy drug most likely to attack cancer in individual patients. The tool, which analyzes RNA expression tied to information about patient outcome... […]
via Bing News